Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

Inclusion Criteria:

* Patients who have undergone CCP testing and patients who have not undergone CCP testing will be considered for enrollment in the study.

  1. Willing to provide written informed consent.
  2. Males ≥65 years old.
  3. Newly diagnosed (≤6 months), treatment-naïve patient with histologically proven localized adenocarcinoma of prostate whose initial treatment has not been decided.
  4. Candidate for and considering AS and yet would be eligible for definitive therapy.
  5. Favorable intermediate-risk disease, defined by the NCCN as follows:

     * predominant Gleason grade 3; AND
     * percentage of positive cores \<50%; AND
     * no more than 1 of the following NCCN intermediate-risk factors:

       * Gleason grade 7
       * T2b-T2c
       * PSA 10-20 ng/mL
  6. Estimated life expectancy ≥10 years.
  7. Can be monitored for disease progression according to standard of care (e.g., current NCCN guidelines).

Exclusion Criteria:

* 1\. Clinical evidence of metastasis or lymph node involvement.
* 2\. Received pelvic radiation prior to biopsy.
* 3\. Received androgen deprivation therapy (ADT) prior to biopsy; however, 5 alpha-reductase inhibitors (5-ARIs) are permitted.
* 4\. Participation in interventional clinical trials.
* 5\. Patient is considering watchful waiting.
* 6\. Has a known history of hypogonadism.